Pfizer Inc (NYSE:PFE) – Pfizer Announces FDA Approval to Include Radiographic Data on Reduction of Progression of Structural Joint Damage for Adults with Moderately to Severely Active Rheumatoid Arthritis in Labeling for XELJANZ® (tofacitinib citrate)

[Business Wire] – Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved a supplemental New Drug Application to update the current label of XELJANZ® 5 mg tablets to include . . . → Read More: Pfizer Inc (NYSE:PFE) – Pfizer Announces FDA Approval to Include Radiographic Data on Reduction of Progression of Structural Joint Damage for Adults with Moderately to Severely Active Rheumatoid Arthritis in Labeling for XELJANZ® (tofacitinib citrate) Similar Articles: Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J, Pharmacyclics drug gets U.S. approval for leukemia Amgen Inc. (NASDAQ:AMGN) ~ Amgen announces MENDEL-2 Phase 3 trial met co-primary endpoints Stock Update: Visa Inc. (NYSE:V) – Visa Inc. announces nomination of Alfred F. Kelly, Jr. and Maynard G. Webb, Jr. for election to the Board of Directors; Gary P. Coughlan announces decision not to stand for re-election in January